Your browser is no longer supported. Please, upgrade your browser.
Epizyme, Inc.
Index- P/E- EPS (ttm)-2.62 Insider Own0.90% Shs Outstand102.51M Perf Week-6.03%
Market Cap354.53M Forward P/E- EPS next Y-2.01 Insider Trans0.00% Shs Float84.57M Perf Month-22.14%
Income-266.70M PEG- EPS next Q-0.32 Inst Own95.00% Short Float9.76% Perf Quarter-36.63%
Sales34.20M P/S10.37 EPS this Y-19.10% Inst Trans-1.26% Short Ratio8.24 Perf Half Y-62.06%
Book/sh-0.20 P/B- EPS next Y15.70% ROA-68.20% Target Price9.83 Perf Year-76.20%
Cash/sh2.04 P/C1.60 EPS next 5Y38.00% ROE-432.90% 52W Range3.12 - 14.30 Perf YTD-69.89%
Dividend- P/FCF- EPS past 5Y7.10% ROI-59.60% 52W High-78.32% Beta1.01
Dividend %- Quick Ratio5.50 Sales past 5Y43.80% Gross Margin73.20% 52W Low-0.80% ATR0.27
Employees304 Current Ratio5.50 Sales Q/Q44.40% Oper. Margin- RSI (14)23.13 Volatility8.03% 7.18%
OptionableYes Debt/Eq- EPS Q/Q-16.30% Profit Margin- Rel Volume2.85 Prev Close3.27
ShortableYes LT Debt/Eq- EarningsNov 09 BMO Payout- Avg Volume1.00M Price3.10
Recom2.10 SMA20-25.65% SMA50-32.61% SMA200-55.50% Volume1,910,998 Change-5.20%
May-07-21Upgrade SVB Leerink Mkt Perform → Outperform $12 → $16
Apr-23-21Resumed Cowen Outperform $14
Mar-31-21Initiated Credit Suisse Outperform $13
Feb-25-21Downgrade Morgan Stanley Overweight → Equal-Weight $14
Dec-21-20Downgrade Jefferies Buy → Hold $14
Apr-01-20Downgrade Oppenheimer Outperform → Perform
Mar-04-20Initiated Barclays Overweight $33
Feb-25-20Reiterated H.C. Wainwright Buy $25 → $36
Jan-24-20Downgrade SVB Leerink Outperform → Mkt Perform
Dec-06-19Upgrade Morgan Stanley Equal-Weight → Overweight
May-30-19Resumed Citigroup Buy
Jan-07-19Upgrade Leerink Partners Mkt Perform → Outperform
Sep-07-18Resumed Morgan Stanley Equal-Weight
Jul-03-18Downgrade Leerink Partners Outperform → Mkt Perform
Jan-24-18Resumed Jefferies Buy $25
Jan-10-18Initiated Morgan Stanley Overweight $20
Nov-02-17Downgrade RBC Capital Mkts Outperform → Sector Perform $20 → $16
Sep-20-17Initiated Jefferies Buy $23
May-10-17Resumed RBC Capital Mkts Outperform $19 → $20
Apr-13-17Initiated Oppenheimer Outperform
Nov-18-21 06:30AM  
Nov-12-21 08:00AM  
Nov-10-21 11:03AM  
Nov-09-21 03:30PM  
Nov-05-21 07:00AM  
Nov-04-21 06:30AM  
Nov-02-21 06:30AM  
Nov-01-21 08:00AM  
Oct-29-21 03:00PM  
Oct-23-21 06:08AM  
Oct-14-21 09:14AM  
Oct-07-21 07:00AM  
Sep-14-21 06:30AM  
Sep-08-21 11:30AM  
Aug-20-21 08:00AM  
Aug-10-21 03:40PM  
Aug-09-21 06:30PM  
Aug-08-21 08:00PM  
Aug-03-21 04:01PM  
Jul-27-21 06:48PM  
Jul-02-21 08:41AM  
Jun-28-21 04:15AM  
Jun-16-21 06:30AM  
Jun-14-21 12:59PM  
May-25-21 06:30AM  
May-12-21 04:01PM  
May-07-21 05:30PM  
May-06-21 08:05AM  
Apr-29-21 06:30AM  
Apr-01-21 12:13PM  
Mar-25-21 11:30AM  
Mar-02-21 12:00PM  
Feb-28-21 01:34AM  
Feb-25-21 10:03AM  
Feb-24-21 06:30AM  
Feb-23-21 08:00PM  
Feb-20-21 09:36AM  
Feb-16-21 06:30AM  
Jan-25-21 07:52AM  
Dec-18-20 02:43PM  
Dec-06-20 11:30AM  
Nov-29-20 12:30PM  
Nov-16-20 05:16AM  
Nov-15-20 11:16PM  
Nov-13-20 12:56PM  
Nov-11-20 04:05PM  
Nov-10-20 05:50AM  
Nov-09-20 10:16AM  
Nov-08-20 09:24AM  
Nov-06-20 07:31PM  
Oct-30-20 06:30AM  
Oct-28-20 12:33PM  
Oct-07-20 03:29PM  
Oct-02-20 09:21AM  
Sep-08-20 06:30AM  
Sep-03-20 11:31AM  
Aug-18-20 01:05PM  
Aug-05-20 11:29AM  
Aug-04-20 05:00PM  
Jul-28-20 06:30AM  
Jul-16-20 06:31PM  
Jun-28-20 09:31AM  
Jun-20-20 07:57AM  
Jun-19-20 10:19AM  
Jun-18-20 01:31PM  
Jun-17-20 01:56PM  
Jun-16-20 07:09AM  
Jun-03-20 11:30AM  
May-26-20 12:55PM  
May-14-20 09:22AM  
May-13-20 05:12PM  
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and adults and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. Epizyme, Inc. has collaboration agreements with Genentech Inc.; Glaxo Group Limited; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; and HUTCHMED (China) Limited. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kutok JefferyChief Scientific OfficerApr 05Sale8.802,02917,85554,028Apr 07 06:15 AM
MOTT DAVID MDirectorMar 26Buy7.9734,486274,817150,900Mar 29 04:30 PM
MOTT DAVID MDirectorMar 25Buy7.9828,231225,283116,414Mar 29 04:30 PM
Bazemore Robert BPresident & CEOMar 25Sale7.8510,32881,075322,626Mar 29 04:30 PM
Bazemore Robert BPresident & CEOFeb 04Sale11.213,89043,607331,977Feb 05 04:41 PM
Beaulieu JosephCorporate ControllerFeb 04Sale11.212272,54513,431Feb 05 04:40 PM
TOMBESI PAOLOChief Financial OfficerFeb 04Sale11.211,02111,44553,465Feb 05 04:40 PM
Agarwal ShefaliChief Medical OfficerFeb 04Sale11.2196910,862104,341Feb 05 04:41 PM
Ros MatthewSee RemarksFeb 04Sale11.2189410,02283,188Feb 05 04:36 PM
Vakiener VictoriaChief Commercial OfficerFeb 04Sale11.218179,15952,685Feb 05 04:32 PM
Bazemore Robert BPresident & CEOJan 25Sale11.416,06969,247248,367Jan 27 08:44 PM
Ros MatthewSee RemarksJan 25Sale11.412,87232,77055,957Jan 27 08:42 PM
Vakiener VictoriaChief Commercial OfficerJan 25Sale11.415996,83527,982Jan 27 08:42 PM
Agarwal ShefaliChief Medical OfficerJan 25Sale11.412,87232,77075,727Jan 27 08:38 PM
Agarwal ShefaliChief Medical OfficerDec 03Sale13.542,52234,14876,089Dec 07 07:00 AM